A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer

A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer Who Are Refractory or Intolerant to Standard Chemotherapy

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222029

Enrollment

Registered

2013-02-22

Start date

2013-03-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or Relapsed Colorectal Cancer

Interventions

investigational material(s) Generic name etc : OCV-C02 INN of investigational material : - Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Patients who have human leukocyte antigen (HLA)-A*24:02 - Patients with histologically confirmed colorectal cancer (adenocarcinoma) - Patients with advanced or relapsed colorectal cancer who are refractory or intolerant to standard chemotherapy - Patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1 at the time of study enrollment

Exclusion criteria

Exclusion criteria: - Patients who are HIV antibody positive - Patients with an active infection - Patients who have or are suspected to have CNS metastasis

Design outcomes

Primary

Measure	Time frame
safety Dose Limiting Toxicity (DLT) Common Terminology Criteria for Adverse Events (CTCAE), ver. 4.0	—

Secondary

Measure	Time frame
safety Safety Common Terminology Criteria for Adverse Events (CTCAE), ver. 4.0 efficacy Tumor response Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, version 1.1 efficacy Immune-response DTH reactions, CTL Measurement, Blood Regulatory T Cell Measurement	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026